Showing posts with label Expanded Access. Show all posts
Showing posts with label Expanded Access. Show all posts

May 14, 2013

$PVCT CEO Letter: PV-10 Compassionate Use Data To Come


When I heard 75% of compassionate use program (CUP) patients were cancer-free (but without any specifics regarding longevity), I wanted context/more information with which to compare this PV-10 success rate. I found some expanded access program data for ipilimumab:


Whether adjusting for patients receiving ipilimumab who were lost to follow-up or not (>20% or more), a "rough" comparison with PV-10 (75%) is notable to say the least.

March 23, 2013

$PVCT CUP: Against The Odds

I imagine Compassionate Use Program ("CUP") patients are on the worse end of the suitable Gaussian or other distribution curve of disease stage. If the x-axis, from left to right, denotes early to later and later disease stage or amount of tumor burden, I would think CUP patients are 2 sigma'ish or worse (i.e., to the far right of the curve). They're likely to be suffering from compromised immune systems with bodies ravaged by failed prior treatments and therapies (e.g., chemotherapies, other immunotherapies, radiation, etc.).

Yet, a supermajority of more than 75 CUP patients -- very compromised, afflicted and ravaged patients with heretofore little to no good treatment options save for PV-10 -- are now cancer-free thanks to the drug?

Hmmm...